Blood Test sST2 Tracked in Children Having Heart Defect Surgery
Measures a blood marker, sST2, in children under 18 before and after heart surgery.
Key facts
- Who runs it
- Martin Schweiger
- Where
- Zurich, SwitzerlandSee the site
- Trial code
- Registry title
- Blood Based Assessment of sST2, Taken During and After Surgery, for Pediatric Patients With Heart Defects to Predict Heart Failure.
- Status
- Recruiting
- People taking part
- 225 people, planned
- Started
- 10 Sept 2025
- Expected to end
- 31 Jan 2029
- Type of study
- Observational
- Record updated
- 17 November 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young people having heart surgery for a heart defect. Blood tests before and after surgery check a marker called sST2 for signs of heart failure.
- Age
- Younger than 18 years (maximum age 18 years).
- Sex
- All sexes can join.
- Disease stage
- Planned surgery with cardiopulmonary bypass (heart-lung machine) for a heart reason, such as congenital heart disease.
- Biomarker or test result
- The trial measures the blood marker sST2; having a certain level is not required to join.
Main reasons for not taking part
- Known genetic conditions that limit life
- Syndrome patients scheduled, or highly likely, to have surgery on more than one organ
- Body weight under 2.5 kg (6 lb) at the time of surgery
- Taking part in an interventional study already
- Not able to understand and sign a consent form in German (child or representative)
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Consented for cardiopulmonary bypass surgery for cardiac reason
- Conversational skills in German (by child and/or representative) to be able to fully understand and sign a written consent in German language
Who cannot take part
- Body weight at time of surgery less than 2.5 kg
- Know genetic life limiting conditions
- Syndrome patients who are scheduled or highly likely to be operated on more than one organ
- Being recruited and enrolled for an interventional study protocol
Where in Switzerland
- University Children's Hospital ZurirchZurich, SwitzerlandContact: Martin Schweiger, Prof, MD, MBATaking people
About the trial
What the trial wants to find out
Patients younger than 18 scheduled for congenital heart surgery will be assessed during and post-operatively as well as at the first follow-up after 9-12 month for the novel biomarker sST2. We will assess the marker independently and in evaluation with other blood biomarkers to evaluate sings of heart failure. Compared to established biomarkers, sST2 promises thereby to be less variable to factors like age or acute kidney injury, rendering it potentially more reliable in the field of congenital cardiac surgery.
The group in the trial
- Patients planned for congenital cardiac surgery
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Biomarker in Congenital Cardiac Surgery - sST2 Marker in Heart Failure in Congenital Heart Disease After Surgery Research and Translational Study
- Plain-language title
- Blood Test sST2 Tracked in Children Having Heart Defect SurgeryGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 17 November 2025